The single most important fact to state at the outset is this: no head-to-head trial human or animal has ever compared BPC-157 against TB-500
A 2026 review in The American Journal of Sports Medicine found that TB-500 may show some promise in early preclinical research (meaning laboratory testing or animal research), but when it comes to high-quality human data on the benefits, were still very much in the more questions than answers phase
Studies suggest that GHK-Cu may have broader therapeutic applications, including reducing scar formation, improving skin texture, and even aiding in conditions like chronic wounds
143 In conscious SHR treated with the AT 1 receptor antagonist candesartan, Ang-(17) evoked a depressor response via activation of the AT 2 receptor, involving the bradykinin-NO cascade
A.BijzetJ.LimburgP
If you experience symptoms such as fatigue, weakness, or numbness and tingling in the hands and feet, seek medical help for proper diagnosis and treatment